Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
Study (n=154) found switching from daily basal insulin glargine U100 to once-weekly icodec (including a loading dose) resulted in increased time in target glucose range as assessed by continuous glucose monitoring (72.9% vs 65.0% for switched vs unswitched, p<0.05).
Source:
Diabetes Care
SPS commentary:
Authors report incidence and rate of adverse effects and hypoglycaemic episodes were comparable.
A related study found treatment with once-weekly insulin icodec was efficacious and well tolerated across all three titration algorithms investigated.
Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes. Slow release of this modified insulin from an albumin depot, together with amino acid changes which make it more resistant to enzyme degradation, result in a prolonged half life of 196 hours.